We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Sues Samsung Bioepis Over Blockbuster Bone Drug Biosimilar
Amgen Sues Samsung Bioepis Over Blockbuster Bone Drug Biosimilar
Amgen filed a lawsuit against Samsung Bioepis for infringing 34 patents that cover denosumab, the active ingredient in Prolia and Xgeva, drugs used to treat bone loss.
